Since we observed that overexpression of cyclin D1 in the KMS‐28BM cell line led to reduced cell adhesion and loss of the CD56 marker, we explored whether cyclin D1 overexpression was correlated with increased levels of circulating tumor cells (CTCs) in a cohort of MM patients from the GEM2012 trial [30]. This evidence concerns the gene NCAM1 and Miyoshi myopathy.